REGENXBIO Inc. (NASDAQ:RGNX) Q3 2025 Earnings Call Transcript
Operator: Welcome, everyone, to the Third Quarter 2025 REGENXBIO Earnings Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded.
Regenxbio Inc. (RGNX)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Redmile Group Jeremy Green | 4,693,389 | $45,291,204 | -2% | 4.41% |
| 2. | AQR Capital Management Cliff Asness | 1,289,655 | $12,445,170 | +39% | 0.01% |
| 3. | Integral Health Asset Management Bhagwan Jay Rao | 1,100,000 | $10,615,000 | +58% | 0.72% |
| 4. | Voss Capital Travis Cocke | 500,000 | $4,825,000 | -14% | 0.24% |
| 5. | Invenomic Capital Management Ali Motamed | 426,904 | $4,119,624 | 0.2% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $22.00 | 49,000 | $1,078,000.00 | 49,000 | 2015-09-22 | Filing | |
| $22.00 | 38,500 | $847,000.00 | 38,500 | 2015-09-22 | Filing | |
| $22.00 | 87,500 | $1,925,000.00 | 1,256,542 | 2015-09-22 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $12.62 | 20,811 | $262,634.82 | 216,162 | 2025-10-09 | Filing | |
| $10.03 | 7,624 | $76,468.72 | 236,973 | 2025-09-29 | Filing | |
| $10.02 | 7,734 | $77,494.68 | 244,597 | 2025-09-10 | Filing | |
| $7.91 | 20,602 | $163,046.29 | 475,103 | 2025-05-12 | Filing | |
| $10.11 | 10,000 | $101,052.00 | 11,286 | 2024-10-01 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 6,370,893 | $61,479,117 | 0% | |
| 2. | 4,037,248 | $38,959,444 | 0% | |
| 3. | 3,338,098 | $32,212,645 | 0% | |
| 4. | 1,984,878 | $19,154,073 | 0% | |
| 5. | 1,852,214 | $17,873,866 | 0% |
News See All
REGENXBIO Publishes Preclinical Data Highlighting RGX-202's Potential for Duchenne Muscular Dystrophy
REGENXBIO Inc. (NASDAQ:RGNX) is one of the biotech stocks to buy according to Wall Street analysts.
10 Biotech Stocks to Buy According to Wall Street Analysts
On July 8, Jared Holz, Mizuho, joined 'Closing Bell Overtime' on CNBC to discuss if the biotech sector is ready for a breakout.
REGENXBIO Inc. (RGNX): A Bull Case Theory
This stock is one of several featured in our latest research.
10 Promising SmallCap Stocks Under $1 Billion Market Cap
SmallCap stocks can often be overlooked by institutional investors, yet they offer outsized return potential for those willing to dig deeper.
REGENXBIO Inc. (NASDAQ:RGNX) Q1 2025 Earnings Call Transcript
Operator: Welcome, everyone to the First Quarter 2025 REGENXBIO Earnings Conference Call. At this time, all participants are in a listen-only mode.
REGENXBIO Inc. (NASDAQ:RGNX) Q4 2024 Earnings Call Transcript
Operator: Welcome everyone to the Fourth Quarter and Year End 2024 REGENXBIO Earnings Conference Call. At this time, all participants are in a listen-only mode.
10 Stocks on Jim Cramer’s Radar
Jim Cramer, the host of Mad Money, addressed some of Wall Street's primary concerns on Tuesday, offering insights into how the White House may interpret the ongoing issues surrounding President Donald...
REGENXBIO Inc. (NASDAQ:RGNX) Q3 2024 Earnings Call Transcript
Operator: Welcome everyone to the Q3 2024 REGENXBIO Earnings Conference Call. [Operator Instructions] Please be advised that today’s conference is being recorded.
REGENXBIO Inc. (NASDAQ:RGNX) Q2 2024 Earnings Call Transcript
Operator: Welcome everyone to the Q2 2024 REGENXBIO's Earnings Conference Call. All lines have been placed on mute to prevent background noise.